



Investor Presentation

June 2025

FORWARD LOOKING STATEMENTS & LEGAL ITEMS

This presentation (the "Presentation") contains "forward-looking information" regarding extractX Ltd. ("extractX" or "eXi" or the "Company") and its subsidiaries. Except for statements of historical fact, certain information contained herein constitutes forward-looking statements which include management's assessment of future plans and operations and are based on current internal expectations, estimates, projections, assumptions and beliefs, which may prove to be incorrect. Often, but not always, forward-looking statements can be identified by the use of words and phrases such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved.

Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made and are based on various assumptions such as: (i) the Company's ability to generate cash flow from operations and obtain necessary financing on acceptable terms; (ii) general economic, financial market, regulatory and political conditions in which the Company operates; (iii) consumer interest in Company solutions and services; (iv) anticipated and unanticipated costs; (v) government regulation of the Company's activities and products; (vi) the timely receipt of any required regulatory approvals; (vii) the Company's ability to obtain qualified staff, equipment and services in a timely and cost efficient manner; the Company's ability to conduct operations in a safe, efficient and effective manner; (viii) and the Company's manufacturing and construction plans, expansion of facilities, its costs and timeframe for completion of such plans.

Forward-looking statements are not guarantees of future performance and undue reliance should not be placed on them. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of goals to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended.

Forward-looking statements contained herein are made as of the date of this Presentation and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results, except as may be required by applicable securities laws. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Securities Laws

This Presentation is for informational purposes and does not constitute an offer for or a solicitation of an offer to purchase the securities referred to herein.

No Reproduction or Distribution

The contents of this presentation are not to be reproduced in anyway or distributed to any third party, including the general public or the media, without the express written consent of the Company. The information contained herein, while obtained from available sources which the Company believes are reliable, is not guaranteed as to its accuracy or completeness. Third Party Information Certain information contained in this Presentation with respect to market trends and products has been obtained or quoted from publicly available sources, such as continuous disclosure documents, independent publications, media articles, third party websites (collectively, the "Publications"). In certain cases, these sources make no representations as to the reliability of the information they publish.

Further, the analyses and opinions reflected in this document are subject to a series of assumptions about future events. There are a number of factors that can cause the results to differ materially from those described in this document and our forecasts. None of the Company or its representatives independently verified the accuracy or completeness of the information contained in the document or assume any responsibility for the completeness or accuracy of the information derived from this document.

Canadian Stock Exchange Status

Recently extractX received word from the Canadian Securities Exchange (CSE), that it had no further comments on-listing statement (the business disclosure section of application) at present time, a milestone in the process for extractX's intention to become a Publicly Traded Company. We were advised by the CSE that the listing will be conditional on a capital raise sufficient to address the business plan at the time of listing. The extractX team will continue to work closely with the CSE to satisfy the listing conditions and once complete, work with capital markets advisors, the business and market conditions to guide the timing on the intended listing. extractX will work closely with investment groups to plan an accretive approach.

The goal is to raise up to \$5M prior to being listed.

Note: All funds are in USD

Global Expansion Problem

The Cannabinoid Industry continues to expand across the globe. Countries are figuring out how to enact legalization – medical, nutraceutical and recreational products in a safe and responsible manner. Industry standards will be set at the highest level for human consumption. Cannabinoid formulators within these countries; pharmaceuticals, food & beverage and supplement providers are demanding that cannabinoids are sourced from EU-GMP/Pharma-Grade, government licenced manufacturers. Those willing to establish at the highest standards for success will demand the highest standards from suppliers, they will demand proven technologies and experience. No matter the cannabinoid delivery method, distillate and isolate will be needed in products.

Opportunity

Opportunity for Global expansion and dominance in the extraction of Cannabinoids, supply of Cannabinoid APIs, smart distribution and market development strategy.

Global leverage: As the global market expands, and EU GMP/Pharma-Grade facilities will be the standard, an extractX Mobile Lab with global operations, and proven technologies, will be a key to overall efficiencies and profitability for all parties.

Technological innovation: Proof of concept for extractX has been successful. Sales of services have been accepted in the marketplace. By combining product design capabilities, compliance, market know-how, manufacturing and process engineering presents opportunities to enhance equipment to deliver new cannabinoid products and services.

Corporate Highlights

- 1 Biotech company experienced in design, engineering, building, commissioning, and supporting mobile extraction facilities for various industries globally.
- 2 Focus on high-grade hemp, cannabis and botanical extraction and processing.
- 3 Mobile Labs contracted, licensed and in operation.
- 4 Global Growth goal to develop and have in use, 20 mobile units globally within the next five years.
- 5 Mobile labs built to EU GMP standards and are Pharma-Grade.
- 6 extractX is a public company and will continue to monitor market conditions and benefits of listing when appropriate.



**A turnkey mobile extraction solution
for hemp and cannabis producers**



**Self-contained operational mobile
suites delivered with the highest in
operating standards to meet Pharma-
Grade and ready to operate**




**Exceptional speed-to-market in as
little as three months avoids lost
revenue for customers**

Proven Technology

The extractX Solution

- extractX is a biotech company with proven technology, that designs, builds, turn-key mobile extraction laboratories built to GPP, cGMP, and EU GMP, Pharma-Grade standards.
- Turnkey labs are mobile - move within a facility or to new operations.
- With 4 lab designs the EML25, EML50, EML100 and EML250, labs can process up to 25,000, 50,000, 100,000 and 250,000 kg of biomass yearly into full plant extract for broad-spectrum distillate and other concentrates.
- Labs come fully equipped with the latest extraction and post-processing technology operated by partner staff technicians, trained by extractX.





Mobile Lab Service Offerings

extractX provides commercial-scale EU GMP/Pharma-Grade that seamlessly fits into new and existing facilities. extractX provides onsite commissioning, training and ongoing support. All Mobile Labs available for 2026 Delivery.

EXTRACTX MOBILE LAB MODELS		EML25	EML50	EML100	EML200
Max Volume Capacity (kg) per Year (7- 10% dry biomass)		25,000	50,000	100,000	250,000
Prepayment (required at time of contract)		\$160,000	\$260,000	\$360,000	\$750,000
Minimum Volume (Kg) Required	Monthly	1,000	1,304	2,222	3,125
	Yearly	12,000	15,648	26,664	37,500

- Additional costs related to shipping, customs, tariffs, taxes and installation.
- Plus a processing fee in accordance with the following table per pound (lb.) or kilogram (kg) of Biomass processed by extractX's Mobile Lab "Base Processing Fee".
- All rates in USD.
- Minimum facility requirements required.
- Rates are subject to change without notice.

Base Processing Fees (CBD-THC)

Biomass Processed (*Cumulative)		Base Processing Fees (*Non-Cumulative)	
lbs.	kg	USD/lbs.	USD/kg
1 – 55,000	1 – 25,000	\$11.36	\$25.00
55,001 – 110,000	25,001 – 50,000	\$9.55	\$21.00
110,001 – 220,000	50,001 – 100,000	\$8.18	\$18.00
220,001 +	100,001 +	\$7.27	\$16.00

As of April 1, 2025

- All rates in USD.
- Rates are subject to change without notice.

Business Strategy Revenue Models



Licensing Model, Partnerships

All inclusive per kg fee on input processing and for the duration of a minimum three-year contract. extractX client manages all operational costs, EML25. EML 50, EML 100 and EML250 models to address various volumes. A non-refundable downpayment pays for part of the build costs.



Master License

Mobile Labs and business model would be licensed. This model to be utilized on expansion into global markets.



Outright Lab Sales

Mobile Labs may eventually (once 5 Labs in market) be produced and sold to cultivator or Licensed Producer's or to licensees, with older Models in use. Servicing fees will generate recurring revenue.

Growth Plan

Current & Future Labs



Currently have contracted lab in:


- Thailand (Chiang Mai)

Projections

Projected Labs

- We anticipate 20 Mobile Lab Contract Signings over the next 5 years.
- Recuring Revenue from processing fees for each kg of Biomass.
- Upfront Fees of a Minimum of \$160,000 US per Lab (for EML25), minimum of \$25k per month or \$300k/yr. Additional processing generate even greater revenue per year.

Cannabis Extract Market Size 2024 to 2034 (USD Billion)



Source: <https://www.precedenceresearch.com/cannabis-extract-market>


<https://www.precedenceresearch.com/cannabis-extract-market>

Recreational Cannabis Legislation Growth (2015-2025)

#	Year	Total Number Countries with Recreational Cannabis Legislation
1	2015	4
2	2016	4
3	2017	4
4	2018	5
5	2019	5
6	2020	6
7	2021	7
8	2022	8
9	2023	9
10	2024	10
11	2025	11

#	Year	Total Number of Countries with Legalization
1	2015	14
2	2016	17
3	2017	22
4	2018	29
5	2019	30
6	2020	33
7	2021	36
8	2022	38
9	2023	41
10	2024	44
11	2025	54

Timeline of Activities



Target Raise

\$5,000,000


Funds to be raised are to be used as follows:

- \$2.75M for final engineering, sourcing of equipment and manufacturing partner(s) for completion of Lab 4, 5 & 6 (upon contract), further design, extractX engineering and build of its new EML25, EML50, EML100 and finalize designs for EML250 – and possible isolation solution lab (as market may demand); financing and administrative costs.
- \$1.25M for listing and go public costs and audits, (legals, etc.), marketing and sales.
- **\$1M for CSE Requirement for Future Cash Flow**


It is expected that all existing debt will be addressed via revenues or shares.

Capital Structure

Pre RTO



Post RTO



extractX has **24,786,786** shares issued and outstanding as of June 30, 2025

Fundraising-to-date

	Term Sheet 1	Term Sheet 2	Term Sheet 3	Term Sheet 4	Term Sheet 5
Round	Friends and Family	Friends and Family	Friends and Family	Friends and Family	Friends and Family
Security	Common shares	Common shares	Common shares + warrants	Common shares	Common shares
Price per Share	\$1.00	\$1.55	\$1.55	\$1.55	\$1.70
Total raised	~ \$1.82 million	~ \$1.14 million	~ \$.76 million	~\$.76 million	~\$.83 million

- Total raised to date under term sheets ~ \$5.31M
- An agreement has been signed and final preparations to go public are underway, when conditions are appropriate.
- Additional growth capital is expected to be raised when public
- Growth is expected through both organic sales growth and accretive acquisitions

Source and Use of Funds

As of June 30, 2025 (in US funds)

Source of Funds	
Founders capital	\$0.30 M
Term Sheet 1	\$1.52 M
Term Sheet 2	\$1.14 M
Term Sheet 3	\$0.76 M
Term Sheet 4	\$0.76 M
Term Sheet 5	\$0.83 M
Standards Council	\$0.11 M
Scientific Research & Experimental Development Credit	\$0.68 M
ACT Program – Federal Contribution	\$0.68 M
Revenue (2018 to 2023)	\$2.33 M
Revenue 2024	\$0.14 M
Revenue 2025 as of June 30, 2025	\$0.15 M
Total	\$ 9.4 M

Use of Funds	
Mobile Lab 1	\$1.29 M
Mobile Lab 2	\$1.10 M
Mobile Labs 3, 4, 5	\$2.05 M
Compliance Consultants & SOPs	\$0.19 M
Other Capital Assets	\$0.42 M
Public Company Costs	\$0.38 M
Operating Costs (2018 to 2023)	\$3.69 M
Operating Costs 2024	\$0.25 M
Operating Costs as of June 30, 2025	\$0.17 M
Total	\$9.54 M

New Investors

New Investors will see their investments in new revenue generating developments.

extractX is open to Investors taking equity or convertible debentures or other options.

extractX Team

Albert Iannantuono, CEO, CMO, Interim CFO: Albert drives the vision, corporate goals, and overall business strategy for extractX. A pioneer in integrated marketing technologies, Albert established his first successful business in 1986 and went on to build a solid track record as an entrepreneur that helped shape the digital industry. A talented leader whose business ranked among Canada's fastest growing companies for several years running, Albert has assembled the strong management team that will drive extractX business forward. His keen business development approach has resulted in early adoption of extractX labs in global markets.

Irma Ettorre, Director, Administration & Controller: Irma brings over 30 years of experience in the administrative, accounting, and human resources fields, with a strong background in managing internal operations as well as the public trading aspects of the company. She has demonstrated expertise in financial oversight, HR management, regulatory compliance, office administration, and stakeholder relations.

Collin Stone, COO: Collin is the founder and innovation force behind extractX. Over the last 25 years, Collin has built and operated successful businesses in North America and overseas. With a career focused on developing new and innovative technologies that deliver business efficiencies, Collin has now turned his attention to revolutionizing the cannabis and hemp industries. Built with Collin's expertise and leadership, extractX mobile labs are counted among the most advanced, automated, and GMP compliant medical-grade facilities in the world.

Geoffrey Martinak, Director, Field Operations: Geoffrey is responsible for the overseeing of the global deployment and operational performance of the extractX mobile extraction labs. He leads the installation, onboarding, and support framework that ensures every lab meets extractX's standards for quality and compliance with EU GMP and Pharma-Grade.. Geoffrey also manages relationships with partners facilities - providing high-level operational guidance and acting as a strategic liaison to align field performance with company objectives. With a background in international business and a strong foundation in project and operations leadership, he brings the insight and execution needed to scale extractX's global field presence.

extractX Board of Directors

Independent Board Members

Andrew Bailey: Andrew is co-founder and COO of ZeroToOne.AI, an advanced AI-powered platform revolutionizing media optimization, targeting and customer relationship management. Developed in collaboration with leading AI researchers from Carnegie Mellon University, the platform enables brands to pinpoint inefficiencies, precisely target audiences, and maximize marketing impact—delivering a decisive strategic and commercial advantage in highly competitive markets. Throughout his career, Andrew has held C-level roles at top agencies within IPG, Omnicom, and WPP, leading transformative work for some of the world's most iconic brands, including P&G, SC Johnson, AT&T, The Coca-Cola Company, Amazon, JPMorgan Chase, Citi, Toyota, and HP. A trusted advisor to CEOs and CMOs, Andrew is a recognized thought leader on the intersection of AI and marketing transformation. A frequent keynote speaker on the future of advertising and AI-driven marketing, he provides deep insights into the evolving landscape of media and consumer engagement.

Mitchell Osak: Mitchell is CEO of Quanta Consulting Inc., a leading cannabis and psychedelics strategy and financial advisory consulting firm. Active in the cannabis sector since 2015, Mitchell has consulted over 100 LPs, extractors, governments and retailers in Canada, the EU, South America, and Africa. He is considered a global thought leader in the cannabis industry. Mitchell was a Partner & Cannabis Advisory lead at MNP and a Managing Director in Grant Thornton's Strategic Advisory Practices. Mitchell is a P&G-trained brand manager and has consulted to a variety of Fortune 500 clients including Amex, Maple Leaf Foods, and IBM.

Non-Independent Board Members

Collin Stone: Collin is the founder and innovation force behind extractX. Over the last 25 years, Collin has built and operated successful businesses in North America and overseas. With a career focused on developing new and innovative technologies that deliver business efficiencies, Collin has now turned his attention to revolutionizing the cannabis and hemp industries. Built with Collin's expertise and leadership, extractX mobile labs are counted among the most advanced, automated, and cGMP compliant medical-grade facilities in the world.

Albert Iannantuono: Albert drives the vision, corporate goals, and overall business strategy for extractX. A pioneer in integrated marketing technologies, Albert established his first successful business in 1986 and went on to build a solid track record as an entrepreneur that helped shape the digital industry. A talented leader whose business ranked among Canada's fastest growing companies for several years running, Albert has assembled the strong management team that will drive extractX business forward. His keen business development approach has resulted in early adoption of extractX labs in global markets.

extractX Advisory Board

David Hyde

David is a global cannabis industry consultant with seven years of hands-on experience guiding cannabis companies and government bodies on matters relating to business/licensing strategy, regulatory/policy approaches, cannabis facility design/operations/security, corporate due diligence, and governance. David's cannabis sector work spans 18 countries and includes engagements with a wide range of cannabis companies, foreign governments, cannabis start-ups, R&D/testing companies, local/regional governments, and investors. David has 34 years of business and leadership experience; before entering the cannabis sector, he was a Corporate Director for a \$17 billion global corporation. David holds an M.Sc. from the University of Leicester, UK.

David Ascott: David has over 25 years of experience in the strategic leadership and management of financial departments, including 12 years at the Chief Financial Officer level. The majority of his CFO experience has been with TSX publicly traded companies with revenues in excess of \$1 Billion. Earlier in his career, he was employed with Ernst & Young for 10 years working in offices in both Canada and Europe. David graduated from the University of Waterloo with a Bachelor of Arts – Honours Accounting in 1992 and has been a Chartered Accountant since 1994.

Jennifer Maccarone: Jennifer is the founder of Total GxP, a global licensing, build, and operations consultancy for compliant cannabis products. Jennifer is also the COO of Final Bell, a company that outsources the production of infused products and single source hardware. Jennifer is an accredited ISO auditor. She has been a pivotal Quality/Regulatory expert in the cannabis industry consulting with several other applicants, 12 of which have been granted a Health Canada Cannabis license. Jennifer has been involved with more than 100 Health Canada audits and achieved a 100% compliance rating. She has also worked at Purdue Pharma in Operations utilizing lean six sigma fundamentals with highly regulated narcotics produced under the most exacting conditions.

Peter Manuel: Peter is the Vice President and Chief Financial Officer of Ucore Rare Metals Inc., a publicly traded mineral exploration and development company. Prior to that, he spent 17 years as a Chartered Accountant providing consulting services to companies, with a focus on the financial services and resource industries. Peter's career includes 10 years in England and The Republic of Ireland providing, strategic planning, corporate finance, and other services to both public and private entities including licensed banks, proprietary trading operations, and international corporate treasuries. He has served as director of Sixth Wave Innovations Inc. since February of 2020.

Peter Tuovi

Peter is a chemical engineering graduate who early in his career chose to become a lawyer. Most of his past 30 years of practice have been spent financing, commercializing, licensing, and distributing new technologies, taking companies public, handling corporate compliance, managing growing pains, preparing and negotiating contracts. He has also been a co-founder, early-stage contributor and board member in numerous businesses including cannabis, retail, fintech, media-entertainment, and marketing-promotions. Peter earned his B.Sc. in Chemical Engineering from Queen's University, holds an LL.B. from the University of Western Ontario, and holds an LL.M from the London School of Economics.

Why Invest

Robust global growth forecasted through 2030

- **Proprietary turn-key laboratories** offer global partners a unique speed-to-market solution
- **Expanding opportunities** with existing partners
- **Growing revenue streams** from exclusive three-year partnerships
- **Recurring monthly revenue** model to re-invest in accretive growth

Exit Strategy

There are several options for the company to create liquidity, the company will explore these options, as to the best for the company and its shareholders

CSE: By transforming our business into a public entity, we will gain access to a wider pool of capital. This move could significantly increase our financial returns and heighten our brand recognition, all while creating acquisition currency for further growth opportunities. However, it's important to bear in mind that this process will require us to meet rigorous corporate governance standards and expose us to market volatility.

Sell: As we engage with more contracted partners, we will have created a more attractive proposition for larger companies who may see the potential for synergies or for filling a gap in their portfolio. The key challenge here is finding the right buyer who appreciates our value and is willing to pay a fair price.



Thank you

Albert Iannantuono

CEO, CMO

905-327-5313

alberti@extractX.com

extractX

ExtractX Proprietary and Confidential Information.

Appendix 1 – Quick Links

- Website: www.extractX.com
- extractX Lab Video Tour: <https://vimeo.com/395971765>
Password: exi2020
- Partner Mark Loik from Aviette BioProcessing
[The Power of Partnership | extractX | Aviette BioProcessing – YouTube](#)
- [Investor Portal](#) (*Access upon request/Password to be supplied*)

Appendix 2 - What they are saying



“Utilizing extractX pharma-grade technology and unique partnership model accelerated our speed to market in Thailand. Global delivery and support capabilities also align perfectly with our growth plans. extractX came to the Salus facility to support the set-up, training and optimization of our extraction capability. We’re truly proud of this partnership with extractX and know their mobile extraction technology is a game changer for the industry.”

Tanadee Pantumkom, Chief Operating Officer
Salus Bioceutical (Thailand) 2021-2023

“I’m delighted to share our fantastic experience with extractX, our trusted partner for over 3 years. Their mobile extraction labs are some of the best we’ve ever used—sophisticated, EU-GMP graded, and incredibly reliable. Their thorough documentation helped us quickly achieve GMP/PICs certification, demonstrating extractX’s commitment to supporting their clients’ regulatory compliance needs. Whenever we’ve faced technical issues, their team responded promptly, no matter the distance between our operations in Thailand and Canada. This kind of support is rare and truly appreciated. The extractX labs are also cost-effective, boosting our production while saving space and investment costs. The comprehensive support we received for installation, training, and process validation has been invaluable. In short, extractX offers state-of-the-art, user-friendly, and scalable solutions. We highly recommend them to any business looking for top-quality extraction and distillation equipment.”

Wittawin Vidthayanon, Chief Operating Officer
Salus Bioceutical (Thailand) 2023- Present

Appendix 2 - What they are saying



"I knew how to build a profitable company with a great product, and I wanted to focus on that side of the business. What I didn't have was the engineering savvy to get the quality I needed, and I knew it was essential to get that right if we were to succeed."

Mark Loik, Owner
Aviette BioProcessing (Kentucky)